Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- المؤلفون: Salvadori, Laura1,2 (AUTHOR) ; Belladonna, Maria Laura3 (AUTHOR) ; Castiglioni, Beatrice4 (AUTHOR) ; Paiella, Martina1 (AUTHOR) ; Panfili, Eleonora3 (AUTHOR) ; Manenti, Tommaso5 (AUTHOR) ; Ercolani, Catia5 (AUTHOR) ; Cornioli, Luca5 (AUTHOR) ; Chiappalupi, Sara2,3 (AUTHOR) ; Gentili, Giulia2,3 (AUTHOR) ; Leigheb, Massimiliano6,7 (AUTHOR) ; Sorci, Guglielmo2,3 (AUTHOR); Bosetti, Michela4 (AUTHOR) ; Filigheddu, Nicoletta1,2 (AUTHOR) ; Riuzzi, Francesca2,3 (AUTHOR)
- المصدر:
Nutrients. Aug2022, Vol. 14 Issue 15, p3053-3053. 19p.
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
The imbalance in osteoblast (OB)-dependent bone formation in favor of osteoclast (OC)-dependent bone resorption is the main cause of loss of tissue mineral mass during bone remodeling leading to osteoporosis conditions. Thus, the suppression of OC activity together with the improvement in the OB activity has been proposed as an effective therapy for maintaining bone mass during aging. We tested the new dietary product, KYMASIN UP containing standardized Withania somnifera, Silybum marianum and Trigonella foenum-graecum herbal extracts or the single extracts in in vitro models mimicking osteoclastogenesis (i.e., RAW 264.7 cells treated with RANKL, receptor activator of nuclear factor kappa-Β ligand) and OB differentiation (i.e., C2C12 myoblasts treated with BMP2, bone morphogenetic protein 2). We found that the dietary product reduces RANKL-dependent TRAP (tartrate-resistant acid phosphatase)-positive cells (i.e., OCs) formation and TRAP activity, and down-regulates osteoclastogenic markers by reducing Src (non-receptor tyrosine kinase) and p38 MAPK (mitogen-activated protein kinase) activation. Withania somnifera appears as the main extract responsible for the anti-osteoclastogenic effect of the product. Moreover, KYMASIN UP maintains a physiological release of the soluble decoy receptor for RANKL, OPG (osteoprotegerin), in osteoporotic conditions and increases calcium mineralization in C2C12-derived OBs. Interestingly, KYMASIN UP induces differentiation in human primary OB-like cells derived from osteoporotic subjects. Based on our results, KYMASIN UP or Withania somnifera-based dietary supplements might be suggested to reverse the age-related functional decline of bone tissue by re-balancing the activity of OBs and OCs, thus improving the quality of life in the elderly and reducing social and health-care costs. [ABSTRACT FROM AUTHOR]
No Comments.